EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

Yoon La Choi, Jong Mu Sun, Juhee Cho, Sanjay Rampal, Joungho Han, Bhash Parasuraman, Eliseo Guallar, Genehee Lee, Jeeyun Lee, Young Mog Shim

Research output: Contribution to journalArticle

Abstract

Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGFR mutation testing. These recommendations are particularly relevant in Asians that have higher EGFR mutation prevalence. This study aims to explore current testing practices, logistics of testing, types of EGFR mutation, and prevalence of EGFR mutations in patients with advanced NSCLC in a large comprehensive cancer center in Korea. Methods: Our retrospective cohort included 1,503 NSCLC patients aged ≥18 years, with stage IIIB/IV disease, who attended the Samsung Medical Center in Seoul, Korea, from January 2007 through July 2010. Trained oncology nurses reviewed and abstracted data from electronic medical records. Results: This cohort had a mean age (SD) of 59.6 (11.1) years, 62.7% were males, and 52.9% never-smokers. The most common NSCLC histological types were adenocarcinoma (70.5%) and squamous cell carcinoma (18.0%). Overall, 39.5% of patients were tested for EGFR mutations. The proportion of patients undergoing EGFR testing during January 2007 through July 2008, August 2008 through September 2009, and October 2009 through July 2010 were 23.3%, 38.3%, and 63.5%, respectively (P

Original languageEnglish (US)
Article numbere56011
JournalPLoS One
Volume8
Issue number2
DOIs
StatePublished - Feb 28 2013

Fingerprint

lung neoplasms
Tertiary Care Centers
Non-Small Cell Lung Carcinoma
Cells
mutation
Mutation
Testing
Korea
testing
Korean Peninsula
cells
Electronic medical equipment
Oncology
Electronic Health Records
squamous cell carcinoma
Logistics
nurses
adenocarcinoma
electronics
Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer : A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital. / Choi, Yoon La; Sun, Jong Mu; Cho, Juhee; Rampal, Sanjay; Han, Joungho; Parasuraman, Bhash; Guallar, Eliseo; Lee, Genehee; Lee, Jeeyun; Shim, Young Mog.

In: PLoS One, Vol. 8, No. 2, e56011, 28.02.2013.

Research output: Contribution to journalArticle

Choi, Yoon La ; Sun, Jong Mu ; Cho, Juhee ; Rampal, Sanjay ; Han, Joungho ; Parasuraman, Bhash ; Guallar, Eliseo ; Lee, Genehee ; Lee, Jeeyun ; Shim, Young Mog. / EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer : A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{238f6793222a48d5b7103768a1669ae5,
title = "EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital",
abstract = "Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGFR mutation testing. These recommendations are particularly relevant in Asians that have higher EGFR mutation prevalence. This study aims to explore current testing practices, logistics of testing, types of EGFR mutation, and prevalence of EGFR mutations in patients with advanced NSCLC in a large comprehensive cancer center in Korea. Methods: Our retrospective cohort included 1,503 NSCLC patients aged ≥18 years, with stage IIIB/IV disease, who attended the Samsung Medical Center in Seoul, Korea, from January 2007 through July 2010. Trained oncology nurses reviewed and abstracted data from electronic medical records. Results: This cohort had a mean age (SD) of 59.6 (11.1) years, 62.7{\%} were males, and 52.9{\%} never-smokers. The most common NSCLC histological types were adenocarcinoma (70.5{\%}) and squamous cell carcinoma (18.0{\%}). Overall, 39.5{\%} of patients were tested for EGFR mutations. The proportion of patients undergoing EGFR testing during January 2007 through July 2008, August 2008 through September 2009, and October 2009 through July 2010 were 23.3{\%}, 38.3{\%}, and 63.5{\%}, respectively (P",
author = "Choi, {Yoon La} and Sun, {Jong Mu} and Juhee Cho and Sanjay Rampal and Joungho Han and Bhash Parasuraman and Eliseo Guallar and Genehee Lee and Jeeyun Lee and Shim, {Young Mog}",
year = "2013",
month = "2",
day = "28",
doi = "10.1371/journal.pone.0056011",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer

T2 - A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

AU - Choi, Yoon La

AU - Sun, Jong Mu

AU - Cho, Juhee

AU - Rampal, Sanjay

AU - Han, Joungho

AU - Parasuraman, Bhash

AU - Guallar, Eliseo

AU - Lee, Genehee

AU - Lee, Jeeyun

AU - Shim, Young Mog

PY - 2013/2/28

Y1 - 2013/2/28

N2 - Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGFR mutation testing. These recommendations are particularly relevant in Asians that have higher EGFR mutation prevalence. This study aims to explore current testing practices, logistics of testing, types of EGFR mutation, and prevalence of EGFR mutations in patients with advanced NSCLC in a large comprehensive cancer center in Korea. Methods: Our retrospective cohort included 1,503 NSCLC patients aged ≥18 years, with stage IIIB/IV disease, who attended the Samsung Medical Center in Seoul, Korea, from January 2007 through July 2010. Trained oncology nurses reviewed and abstracted data from electronic medical records. Results: This cohort had a mean age (SD) of 59.6 (11.1) years, 62.7% were males, and 52.9% never-smokers. The most common NSCLC histological types were adenocarcinoma (70.5%) and squamous cell carcinoma (18.0%). Overall, 39.5% of patients were tested for EGFR mutations. The proportion of patients undergoing EGFR testing during January 2007 through July 2008, August 2008 through September 2009, and October 2009 through July 2010 were 23.3%, 38.3%, and 63.5%, respectively (P

AB - Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGFR mutation testing. These recommendations are particularly relevant in Asians that have higher EGFR mutation prevalence. This study aims to explore current testing practices, logistics of testing, types of EGFR mutation, and prevalence of EGFR mutations in patients with advanced NSCLC in a large comprehensive cancer center in Korea. Methods: Our retrospective cohort included 1,503 NSCLC patients aged ≥18 years, with stage IIIB/IV disease, who attended the Samsung Medical Center in Seoul, Korea, from January 2007 through July 2010. Trained oncology nurses reviewed and abstracted data from electronic medical records. Results: This cohort had a mean age (SD) of 59.6 (11.1) years, 62.7% were males, and 52.9% never-smokers. The most common NSCLC histological types were adenocarcinoma (70.5%) and squamous cell carcinoma (18.0%). Overall, 39.5% of patients were tested for EGFR mutations. The proportion of patients undergoing EGFR testing during January 2007 through July 2008, August 2008 through September 2009, and October 2009 through July 2010 were 23.3%, 38.3%, and 63.5%, respectively (P

UR - http://www.scopus.com/inward/record.url?scp=84874544125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874544125&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0056011

DO - 10.1371/journal.pone.0056011

M3 - Article

C2 - 23468851

AN - SCOPUS:84874544125

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e56011

ER -